论文部分内容阅读
目的通过检测皮质类固醇(corticosteroids,CS)受体α及βmRNA在接受鼻腔CS治疗后不同疗效的两组常年性持续性变应性鼻炎(AR)患者鼻黏膜的定量表达,探讨在不同组AR鼻黏膜组织中CS-α和CS-β的表达意义。方法通过随访120例门诊AR患者后筛查出65例常年性持续性AR患者,其中CS敏感组36例,CS抵抗组29例。采用荧光定量反转录聚合酶链反应(FQ-RT-PCR)方法,检测65例常年性持续性AR患者鼻黏膜组织中CS-αmRNA和CS-βmRNA的定量表达。结果在CS抵抗组鼻黏膜组织中CS-βmRNA表达[(5.62±1.28)×102拷贝/μg]均高于CS敏感组[(4.62±0.48)×102拷贝/μg,t=-6.67,P<0.01]和正常鼻黏膜组[(5.32±0.55)×102拷贝/μg,t=-8.29,P<0.01],并在该两组之间差异均有统计学意义。CS-αmRNA与CS-βmRNA的比值在CS敏感组(658.32±65.16)与CS抵抗组(525.70±68.10)间差异有统计学意义(t=10.16,P<0.01)。结论常年性持续性AR患者中的CS-βmRNA高表达、CS-αmRNA表达下调提示CS抵抗的存在,CS-β在评价AR患者对CS治疗疗效上有一定作用。
Objective To investigate the quantitative expression of nasal mucosa in two groups of perennial persistent allergic rhinitis (AR) patients with different therapeutic effects after nasal CS treatment by detecting the receptor α and β mRNA of corticosteroids (CS) Expression of CS-α and CS-β in mucosal tissues. Methods A total of 65 patients with persistent persistent AR were screened out from 120 patients with AR who were followed up, among which 36 were CS-sensitive group and 29 were CS-resistant group. The quantitative expression of CS-αmRNA and CS-βmRNA in nasal mucosa of 65 patients with persistent perennial AR were detected by fluorescence quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR). Results CS-βmRNA expression in nasal mucosa of CS resistant group [(5.62 ± 1.28) × 102 copies / μg] was significantly higher than that in CS sensitive group [(4.62 ± 0.48) × 102 copies / μg, t = -6.67, P < 0.01] and normal nasal mucosa [(5.32 ± 0.55) × 102 copies / μg, t = -8.29, P <0.01), and the differences between the two groups were statistically significant. The ratio of CS-αmRNA to CS-βmRNA in CS sensitive group (658.32 ± 65.16) and CS resistant group (525.70 ± 68.10) was significantly different (t = 10.16, P <0.01). Conclusions CS-βmRNA is highly expressed in perennial persistent AR patients. The down-regulation of CS-αmRNA expression suggests the existence of CS resistance. CS-β may play an important role in evaluating the therapeutic effect of CS in AR patients.